Skip to main content Skip to search Skip to main navigation

EMA: Concept Paper on Active Substances and Nitrosamine Impurities

On 26 July 2022, the EMA published a concept paper to start the process for the revision of the Guideline on the chemistry of active substances. The document dates from 2016 and does not consider the nitrosamine issue that has developed in recent years.

The critical need to revise and update this important guideline was identified when the "Lessons learnt report" on impurities in sartan medicines was compiled.

What can be expected in terms of content?
Recommendations for the prevention, risk reduction and control of N-nitrosamines, but also for other "contaminants of concern" (CoC) and potent toxins will be included. Also to be tackled are

  • Strategies for process development
  • The subject areas of raw materials, starting materials and intermediate products and their potential contamination risk
  • The use of recycled materials
  • Specific control options for nitrosamines

The EMA Quality Working Party (QWP) has appointed two rapporteurs as well as experts from different Member States with expertise in this field to the drafting group. The group will be supported by an observer from the European Directorate for Quality of Medicines (EDQM), who will work closely with the QWP expert group on nitrosamines.

What is the schedule?

The concept paper will be available for comments until 31 October 2022. Following this, a draft document will be prepared, which will then be released for comments for six months.


Source:

EMA: Concept Paper on the revision of the guideline on the chemistry of active substances
EMA: Guideline on the chemistry of active substances

 

Meet the GMP Compliance Adviser

The GMP Compliance Adviser is the world's largest knowledge portal for quality management in the pharma business. 

The demo access is non-binding and ends automatically.

Test it now for free

You may also be interested in the following articles:

EMA: Revision of Annex 6 - Manufacture of Medicinal Gases

EMA: Revision of Annex 6 - Manufacture of Medicinal Gases

EMA and PIC/S have published a concept paper announcing a targeted revision of Annex 6 Manufacture of Medicinal Gases of the EU GMP Guide. The last update dates from 2010. The revision aims to reflect current manufacturing practice, technological progress and lessons learned from the COVID-19 pandemic.

Read more
EMA: Concept Paper on the Revision of Annex 15

EMA: Concept Paper on the Revision of Annex 15

EMA and PIC/S have published a concept paper outlining a targeted revision of Annex 15 (Qualification and Validation).

Read more
What do Typical Manufacturing Processes for Sterile Products look like?

What do Typical Manufacturing Processes for Sterile Products look like?

Here's the answer:
Read more
Human Resource Management as a Key to Success

Human Resource Management as a Key to Success

The pharmaceutical industry in Germany and other countries, too, faces considerable challenges in the area of human resource management. These problems have far-reaching implications for the competitiveness and innovative power of the industry.

Read more
EMA: Reflection Paper on the Qualification of Non-Mutagenic Impurities (NMIs)

EMA: Reflection Paper on the Qualification of Non-Mutagenic Impurities (NMIs)

The EMA has published a new reflection paper outlining its current thinking on the qualification of non-mutagenic impurities (NMIs). The paper addresses recommended approaches for evaluating the safety of new or increased impurity levels, particularly when such impurities exceed the ICH Q3A/Q3B qualification thresholds and are identified after completion of non-clinical toxicology studies.

Read more
EMA: Discussions on the Revised ERA Guideline

EMA: Discussions on the Revised ERA Guideline

During the second industry stakeholder webinar on the revised guideline on environmental risk assessment (ERA) for medicinal products for human use, the European Medicines Agency (EMA) addressed key implementation challenges observed during the first year of application.
Read more
Previous
Next